{"Exaggerate": "The claim states that prescription drug prices in the US are, on average, 4 times higher than in other countries. The provided evidence supports this claim, indicating that drug prices in the US can range from 708% to 4,833% higher than the combined mean price of the other 11 countries measured. Additionally, other studies mentioned in the expert's verdict also support the claim, showing that certain drugs can be up to 4 times higher in the US compared to other countries.", "Lack enough support": "While the claim is supported by evidence from the U.S. House's Ways and Means Committee and other studies, it is unclear if this evidence is extensive enough to provide a comprehensive comparison of prescription drug prices in the US and other countries. The claim could benefit from additional supporting data or studies.", "Falters at times": "The expert mentions that measuring drug prices accurately, both in the US and abroad, can be challenging. This suggests that there may be limitations or inconsistencies in the data used to support the claim, which could weaken its overall validity.", "Problematic assumption": "The claim assumes that the higher prices charged by prescription drug companies in the US are unjustified or excessive compared to other countries. While the evidence presented supports the claim, it does not delve into the underlying reasons or factors contributing to these price differences. Without further analysis, it is difficult to determine if the assumption is valid.", "Exist alternative explanation": "The claim does not consider alternative explanations for the higher prescription drug prices in the US. It is possible that factors such as research and development costs, regulatory differences, or market dynamics contribute to the price disparities. The evidence provided does not address these potential alternative explanations."}